D.A. Davidson & Co’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $406K | Sell |
525
-19
| -3% | -$14.5K | ﹤0.01% | 1244 |
|
|
2025
Q4 | $420K | Sell |
544
-66
| -11% | -$44.8K | ﹤0.01% | 1202 |
|
|
2025
Q3 | $343K | Buy |
610
+1
| +0.2% | +$565 | ﹤0.01% | 1261 |
|
|
2025
Q2 | $320K | Sell |
609
-123
| -17% | -$68.7K | ﹤0.01% | 1203 |
|
|
2025
Q1 | $464K | Sell |
732
-21
| -3% | -$14.4K | ﹤0.01% | 1059 |
|
|
2024
Q4 | $536K | Sell |
753
-68
| -8% | -$57.1K | ﹤0.01% | 986 |
|
|
2024
Q3 | $863K | Buy |
821
+40
| +5% | +$44.5K | 0.01% | 820 |
|
|
2024
Q2 | $821K | Buy |
781
+72
| +10% | +$69.8K | 0.01% | 797 |
|
|
2024
Q1 | $682K | Hold |
709
| – | – | 0.01% | 871 |
|
|
2023
Q4 | $623K | Buy |
709
+103
| +17% | +$84.8K | 0.01% | 865 |
|
|
2023
Q3 | $499K | Sell |
606
-301
| -33% | -$237K | 0.01% | 910 |
|
|
2023
Q2 | $652K | Sell |
907
-116
| -11% | -$89.4K | 0.01% | 833 |
|
|
2023
Q1 | $841K | Buy |
1,023
+439
| +75% | +$331K | 0.01% | 736 |
|
|
2022
Q4 | $421K | Sell |
584
-14
| -2% | -$10.3K | 0.01% | 911 |
|
|
2022
Q3 | $412K | Buy |
598
+57
| +11% | +$35.9K | 0.01% | 880 |
|
|
2022
Q2 | $320K | Sell |
541
-15
| -3% | -$9.75K | ﹤0.01% | 989 |
|
|
2022
Q1 | $388K | Buy |
556
+58
| +12% | +$36.7K | ﹤0.01% | 973 |
|
|
2021
Q4 | $314K | Buy |
498
+15
| +3% | +$9.22K | ﹤0.01% | 1039 |
|
|
2021
Q3 | $292K | Sell |
483
-20
| -4% | -$12.4K | ﹤0.01% | 1025 |
|
|
2021
Q2 | $281K | Buy |
503
+42
| +9% | +$21.3K | ﹤0.01% | 1017 |
|
|
2021
Q1 | $218K | Buy |
+461
| New | +$224K | ﹤0.01% | 1066 |
|
|
2017
Q3 | – | Sell |
-105
| Closed | -$51K | – | 1790 |
|
|
2017
Q2 | $51K | Sell |
105
-35
| -25% | -$15.3K | ﹤0.01% | 1528 |
|
|
2017
Q1 | $54K | Sell |
140
-85
| -38% | -$31.5K | ﹤0.01% | 1494 |
|
|
2016
Q4 | $81K | Buy |
225
+36
| +19% | +$13.7K | ﹤0.01% | 1396 |
|
|
2016
Q3 | $75K | Buy |
189
+125
| +195% | +$50.1K | ﹤0.01% | 1346 |
|
|
2016
Q2 | $22K | Buy |
64
+24
| +60% | +$9.24K | ﹤0.01% | 1734 |
|
|
2016
Q1 | $14K | Buy |
40
+16
| +67% | +$6.59K | ﹤0.01% | 1826 |
|
|
2015
Q4 | $13K | Buy |
24
+7
| +41% | +$3.79K | ﹤0.01% | 1835 |
|
|
2015
Q3 | $7K | Buy |
17
+1
| +6% | +$537 | ﹤0.01% | 1946 |
|
|
2015
Q2 | $8K | Hold |
16
| – | – | ﹤0.01% | 1931 |
|
|
2015
Q1 | $7K | Buy |
16
+9
| +129% | +$3.81K | ﹤0.01% | 1867 |
|
|
2014
Q4 | $2K | Sell |
7
-35
| -83% | -$13.8K | ﹤0.01% | 2035 |
|
|
2014
Q3 | $14K | Buy |
42
+7
| +20% | +$2.35K | ﹤0.01% | 1761 |
|
|
2014
Q2 | $9K | Hold |
35
| – | – | ﹤0.01% | 1824 |
|
|
2014
Q1 | $10K | Sell |
35
-239
| -87% | -$73.6K | ﹤0.01% | 1806 |
|
|
2013
Q4 | $74K | Buy |
+274
| New | +$78.8K | ﹤0.01% | 1197 |
|
Other funds holding REGN
VCM
N
D.A. Davidson & Co's REGN Position: Q1 2026 in Review
D.A. Davidson & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 3.5% in Q1 2026, selling an estimated $14.5K and leaving 525 shares worth $406K. The position accounts for ﹤0.01% of the portfolio, ranked #1244.
D.A. Davidson & Co first reported a position in REGN in Q4 2013 and has held it in 36 quarters since. The position peaked at $863K in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- D.A. Davidson & Co held 525 shares of Regeneron Pharmaceuticals worth $406K as of Q1 2026.
- D.A. Davidson & Co sold 19 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $14.5K.
- Regeneron Pharmaceuticals made up ﹤0.01% of D.A. Davidson & Co's portfolio in Q1 2026, its #1244 holding.
- D.A. Davidson & Co first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 36 quarters since.
- D.A. Davidson & Co's Regeneron Pharmaceuticals position peaked at $863K in Q3 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on D.A. Davidson & Co's 13F filing for Q1 2026, filed 5 May 2026.